First Time Loading...

Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 5.4 USD 3.85%
Updated: May 15, 2024

Aurinia Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurinia Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Comparables:
ZYME
TH
RPTX
FUSN
EDT

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Interest Income Expense
$13.7m
CAGR 3-Years
157%
CAGR 5-Years
N/A
CAGR 10-Years
34%
Zymeworks Inc
NYSE:ZYME
Interest Income Expense
$18.5m
CAGR 3-Years
36%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Interest Income Expense
-$8.1m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Interest Income Expense
$13.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Interest Income Expense
$4.1m
CAGR 3-Years
131%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Interest Income Expense
-CA$3.2m
CAGR 3-Years
-373%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Aurinia Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
13.7m USD

Based on the financial report for Mar 31, 2024, Aurinia Pharmaceuticals Inc's Interest Income Expense amounts to 13.7m USD.

What is Aurinia Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
34%

Over the last year, the Interest Income Expense growth was 58%. The average annual Interest Income Expense growth rates for Aurinia Pharmaceuticals Inc have been 157% over the past three years , and 34% over the past ten years .